A phase I dose escalation trial of MAGE-A3- and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN)

• Published in: Cancer Immunology, Immunotherapy Immunotherapy, 2015-03, Vol.64 (3), p.367-379
• Main Authors: Zandberg, Dan P., Rollins, Sandra, Goloubeva, Olga, Morales, Robert E., Tan, Ming, Taylor, Rodney, Wolf, Jeffrey S., Schumaker, Lisa M., Cullen, Kevin J., Zimrin, Ann, Ord, Robert, Lubek, Joshua E., Suntharalingam, Mohan, Papadimitriou, John C., Mann, Dean, Strome, Scott E., Edelman, Martin J.
• Format: Article
• Language: English
• Subjects: Adult; Aged; Antibodies; Antigens; Antigens, Neoplasm - immunology; Cancer Research; Cancer therapies; Cancer Vaccines - administration & dosage; Cancer Vaccines - immunology; Carcinoma, Squamous Cell - immunology; Carcinoma, Squamous Cell - therapy; Cohort Studies; Disease Progression; Dose-Response Relationship, Immunologic; Drug dosages; Enzymes; Female; Granulocyte-Macrophage Colony-Stimulating Factor - administration & dosage; Head & neck cancer; Head and Neck Neoplasms - immunology; Head and Neck Neoplasms - therapy; Human papillomavirus; Human papillomavirus 16; Human papillomavirus 16 - immunology; Humans; Immunologic Factors - administration & dosage; Immunologic Factors - immunology; Immunology; Lymphocytes; Male; Medicine; Medicine & Public Health; Melanoma; Metastasis; Middle Aged; Neoplasm Proteins - immunology; Oncology; Original Article; Otolaryngology; Patients; Peptides; Radiation; Squamous Cell Carcinoma of Head and Neck; Toxicity; Tumors; Vaccines; Vaccines, Subunit - administration & dosage; Vaccines, Subunit - immunology
• ISSN: 0340-7004; 1432-0851
• DOI: 10.1007/s00262-014-1640-x

Background We conducted a phase I dose escalation study to evaluate the safety and immunologic response to peptide immunomodulatory vaccines GL-0810 (HPV16) and GL-0817 (MAGE-A3) in HPV16 and MAGE-A3-positive RM–SCCHN patients, respectively. Methods Three dose levels (500, 1,000, and 1,500 µg) of GL-0810 or GL-0817 with adjuvants Montanide (1.2 ml) and GM-CSF (100 µg/m2) were administered subcutaneously q2 weeks for a total of four vaccinations in HPV16 and MAGE-A3-positive RM–SCCHN patients, respectively. Results Nine and seven patients were enrolled in the HPV16 and MAGE-A3 cohorts, respectively. No dose-limiting toxicities were observed, and toxicity was predominantly local and grade 1 (erythema, pain, and itching at the injection site). In those patients who received all four vaccinations, 80 % (4/5) of the HPV16 cohort and 67 % (4/6) of the MAGE-A3 cohort developed antigen-specific T cell and antibody responses to the vaccine. Significant concordance between T cell and antibody responses was observed for both groups. No clear dose–response correlation was seen. All patients progressed by RECIST at first repeat imaging, except for one patient in the MAGE-A3 500 µg cohort who had stable disease for 10.5 months. The median PFS and OS for the MAGE-A3 cohorts were 79 and 183 days, respectively, and for the HPV16 cohort 80 and 196 days, respectively. Conclusions GL-0810 and GL-0817 were well tolerated in patients with RM–SCCHN with T cell and antibody responses observed in the majority of patients who received all four vaccinations.